Lab Spotlight

Vaccine Candidate May Prevent Zika Virus Infection

Dept. of Health and Human Services

In response to the public health emergency posed by the Zika virus infection, researchers at the National Institute for Allergy and Infectious Diseases (NIAID) rapidly developed a vaccine candidate to prevent Zika virus infection. NIAID clinicians tested the vaccine candidate in a Phase I clinical trial that was safe and immunogenic. Phase II clinical trials are underway in Latin America. If this vaccine candidate proves to be effective, it could be the first licensed DNA-based vaccine for humans that could provide protection from the neurological disorders caused by Zika virus infection.

Lab Spotlight